Transitional Cell Carcinoma (TCC) kidney cancer is a rare form of cancer that initially may not present any symptoms. This type of cancer affects the lining of the kidney or the ureters, which are the tubes responsible for carrying urine from the kidneys to the bladder. The kidneys play a crucial role in filtering waste products from the blood, which then accumulates in the bladder. In some cases, individuals may not experience symptoms of TCC kidney cancer until the tumor progresses.
The symptoms of Upper Urinary Tract Urothelial Carcinoma (UUTUC), previously known as TCC kidney cancer, can vary depending on the stage of the cancer. Individuals with early-stage UUTUC may not exhibit any symptoms initially. However, as the tumor grows, common symptoms may include the presence of blood in the urine, persistent back pain, extreme fatigue, unexplained weight loss, and painful or frequent urination. These symptoms can also be associated with other conditions, so it is essential to seek medical advice for proper diagnosis and treatment.
The development of UUTUC is primarily due to changes in the way transitional cells in the renal pelvis and ureters function. These changes typically involve alterations in cell growth and division leading to the formation of cancer. Several risk factors can increase the likelihood of DNA damage in cells, ultimately contributing to the development of UUTUC. These factors include a personal history of bladder cancer, smoking, a family history of Lynch syndrome, excessive use of specific pain medications, exposure to certain substances like aristolochic acid found in plants, dyes, and chemicals used in the production of leather goods.
Healthcare professionals employ various methods to diagnose UUTUC, which may include analyzing the patient’s medical history, physical examination, and conducting tests such as urinalysis, ureteroscopy, urine cytology, CT or CAT scans, ultrasound scans, MRI scans, and biopsies. These diagnostic procedures aid in confirming the presence of UUTUC and determining the extent of cancer spread within the renal pelvis and ureter or to other parts of the body.
Treatment for UUTUC depends on factors such as the patient’s overall health, the cancer stage, and the presence of other medical conditions. Available treatment options may include endoscopic ablation, chemotherapy, and surgery. Endoscopic ablation involves the use of a small tube inserted into the ureter via the bladder to destroy cancer cells using a laser or heat source. Chemotherapy utilizes anticancer drugs to combat cancer cells, either before, after, or during surgery. Surgical interventions like nephroureterectomy, segmental ureterectomy, and lymph node dissection may be performed to remove the affected parts of the kidney, ureter, or bladder.
The survival rate of early-stage TCC kidney cancer can be more than 90%, according to the National Cancer Institute (NCI). However, when the cancer has spread to other areas or beyond the inner lining of the bladder, the survival rate can drop significantly to 15% or lower. The aggressiveness of TCC kidney cancer is influenced by various factors, with more advanced stages demonstrating higher levels of aggressiveness. Overall, the outlook for individuals with TCC kidney cancer is generally favorable, but is closely linked to the stage and spread of the tumor.
Transitional Cell Carcinoma (TCC) kidney cancer is a complex and rare form of cancer that requires prompt diagnosis and appropriate treatment. Understanding the symptoms, causes, diagnosis, and treatment options for UUTUC is essential for improving patient outcomes and quality of life. By raising awareness and promoting early detection, individuals at risk of TCC kidney cancer can seek timely medical intervention, leading to better prognoses and treatment outcomes.
Leave a Reply